Obeldesivir obeldesivir (GS-5245) PHASE2
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Peak Sales Est$1000M
Formulations[]
Companies
GILD (ORIGINATOR)100%
Mechanism: Nucleoside analog antiviral
Expert: Oral nucleoside analog prodrug metabolized to active triphosphate. Inhibits viral RNA-dependent RNA polymerase.
Everyday: An oral antiviral that stops viruses from copying their genetic material.
Targets: []
Programs (1)
IndicationStageKey StudyRegional Status
Acute RSV infectionPHASE2Phase 2 RSV
Data from Supabase · Updated 2026-03-24